A. Mohamed

发表

Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance.

D. Ishengoma, C. Mandara, M. Warsame, 2024, The Lancet. Infectious diseases.

Evidence of artemisinin partial resistance in North-western Tanzania: clinical and drug resistance markers study

D. Ishengoma, C. Mandara, M. Warsame, 2024, medRxiv.

Microsatellites reveal high polymorphism and high potential for use in anti-malarial efficacy studies in areas with different transmission intensities in mainland Tanzania

R. Njau, D. Ishengoma, R. Kavishe, 2023, medRxiv.

Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine-pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional survey.

D. Ishengoma, C. Mandara, F. Molteni, 2024, The Lancet. Microbe.

Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania

R. Njau, D. Ishengoma, C. Mandara, 2023, medRxiv.

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019

B. Ngasala, D. Ishengoma, B. Mmbando, 2024, Malaria journal.

Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania

B. Ngasala, M. Chiduo, Samweli Bushukatale, 2024, Malaria journal.

Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021

B. Ngasala, N. Lucchi, D. Ishengoma, 2024, bioRxiv.